Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Crinetics Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $13.0 million
Deal Type: Licensing Agreement February 28, 2022
Details:
UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.
Lead Product(s): Upacicalcet Sodium
Therapeutic Area: Endocrinology Product Name: Upasita
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kissei Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021